Pneumococcus (Streptococcus pneumoniae) causes potentially life-threatening diseases including pneumonia and meningitis. Pneumococcal infections are thought to kill approximately a million young children worldwide each year, although the success of vaccination programmes has led to a dramatic fall in the number of cases in countries such as the UK and the USA.
These vaccines recognise the bacteria by its polysaccharide, the material found on the outside of the bacterial cell. There are more than 90 different kinds – or ‘serotypes’ – of the bacteria, each with a different polysaccharide coating.
In 2000, the USA introduced a pneumococcal vaccine that targeted seven of the 90 serotypes. This ‘7-valent’ vaccine was extremely effective and had a dramatic effect on reducing disease among the age groups targeted.
Remarkably, the vaccine has also prevented transmission from young children to adults, resulting in tens of thousands fewer cases of pneumococcal disease each year. The same vaccine was introduced in the UK in 2006 and was similarly successful; in spite of the success of the vaccine programmes, however, some pneumococcal strains continued to cause disease by camouflaging themselves from the vaccine.
In research funded by the Wellcome Trust, scientists at the University of Oxford and at the Centers for Disease Control and Prevention in Atlanta studied what happened after the introduction of this vaccine in the USA. They used the latest genomic techniques combined with epidemiology to understand how different serotypes of the pneumococcus bacteria evolve to replace those targeted by the initial vaccine.
The researchers found bacteria that had evaded the vaccine by swapping the region of the genome responsible for making the polysaccharide coating with the same region from a different serotype, not targeted by the vaccine. This effectively disguised the bacteria, making it invisible to the vaccine. This exchange of genome regions occurred during a process known as recombination, whereby one of the bacteria replaces a piece of its own DNA with a piece from another bacterial type.
Dr Rory Bowden, from the University of Oxford, explains: “Imagine that each strain of the pneumococcus bacteria is a class of schoolchildren, all wearing the school uniform. If a boy steals from his corner shop, a policeman – in this case the vaccine – can easily identify which school he belongs to by looking at his uniform. But if the boy swaps his sweater with a friend from another school, the policemen will no longer be able to recognise him and he can escape. This is how the pneumococcus bacteria evade detection by the vaccine.”
Dr Bowden and colleagues identified a number of recombined serotypes that had managed to evade the vaccine. One in particular grew in frequency and spread across the USA from east to west over several years.
Dr Bowden and colleagues also showed that during recombination, the bacteria traded several other parts of the genome at the same time, a phenomenon never before observed in natural populations of pneumococcus. This is particularly concerning because recombination involving multiple fragments of DNA enables the rapid simultaneous exchange of key regions of the genome within the bug, potentially allowing it to quickly develop antibiotic resistance.
The original 7-valent vaccine in the USA has now been replaced by a 13-valent vaccine, which targets 13 different serotypes, including the particular type that had escaped the original vaccine. In the UK, the 7-valent vaccine resulted in a substantial drop in disease overall. This overall effect was a mixture of a large drop in frequency of the serotypes targeted by the vaccine with some growth in serotypes not targeted by the vaccine. The 13-valent vaccine was introduced in the UK in 2010.
Derrick Crook, Professor of Microbiology at the University of Oxford and Infection Control Doctor at the Oxford University Hospitals NHS Trust, says: “Childhood vaccines are very effective at reducing disease and death at a stage in our lives when we are susceptible to serious infections. Understanding what makes a vaccine successful and what can cause it to fail is important.
“We should now be able to understand better what happens when a pneumococcal vaccine is introduced into a new population. Our work suggests that current strategies for developing new vaccines are largely effective but may not have long-term effects that are as successful as hoped.”
Dr Bernard Beall, a scientist at the Centers for Disease Control and Prevention commented: “The current vaccine strategy of targeting predominant pneumococcal serotypes is extremely effective; however, our observations indicate that the organism will continue to adapt to this strategy with some measurable success.”
The Wellcome Trust, which part-funded this research, views combating infectious disease and maximising the health benefits of genetic research as two of its strategic priorities. Dr Michael Dunn, Head of Molecular and Physiological Sciences at the Wellcome Trust, commented: “New technologies allow us to rapidly sequence disease-causing organisms and see how they evolve. Coupled with collaborations with epidemiologists, we can then track how they spread and monitor the potential impact this will have on vaccine efficiency. This will provide useful lessons for vaccine implementation strategies.”
Image: A colour-enhanced SEM of a colony of Streptococcus pneumoniae. Credit: Debbie Marshall, Wellcome Images.
Senior Media Officer
T +44 (0)20 7611 7329
E [email protected]
Notes for editors
Golubchik T et al. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event. Nat Genet 2012 (epub ahead of print).
Pneumococcal disease in the UK
Approximately 5000-6000 cases of invasive pneumococcal disease are reported annually to the Health Protection Agency, Centre for Infections. In addition, there are an estimated 40 000 hospitalisations due to pneumococcal pneumonia, 40 000 GP consultations for pneumococcal related community acquired pneumonia and over 63 000 for pneumococcal otitis media in England and Wales each year.
Source: Health Protection Agency.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
About Oxford University’s Medical Sciences Division
Oxford University’s Medical Sciences Division is recognized internationally for its outstanding research and teaching, attracting the brightest minds from all over the world. It is one of the largest biomedical research centres in Europe, with over 2500 people involved in research and more than 2800 students, and brings in around two-thirds of Oxford University’s external research income. Listed by itself, that would make it the fifth largest university in the UK in terms of research grants and contracts.
Oxford is home to the UK’s top-ranked medical school, and partnerships with the local NHS Trusts enable patients to benefit from the close links between medical research and healthcare delivery. Fourteen winners of the Nobel Prize for Physiology or Medicine worked or were educated at Oxford, and the division is home to 29 Fellows of the Royal Society and 68 Fellows of the Academy of Medical Sciences.